Related Experiment Videos
Cardiac hydatid disease: report of two cases
Duncan Snodgrass1, Steven Blome
1Department of Radiology, Royal North Shore Hospital, Sydney. duncmac@ozemail.com.au
Insights
Cardiac hydatid disease is a rare condition affecting less than 2% of patients. Early diagnosis via imaging and long-term albendazole chemotherapy are crucial for managing this potentially fatal infection.
Area of Science:
- Cardiology
- Infectious Diseases
- Parasitology
Background:
- Hydatid disease, caused by Echinococcus granulosus, rarely affects the heart.
- Cardiac involvement can be systemic or isolated, often presenting with vague symptoms.
Observation:
- The condition is frequently asymptomatic for extended periods.
- Diagnostic imaging is vital for accurate assessment and treatment planning.
- Surgical resection (cystopericystectomy) followed by albendazole chemotherapy is the standard treatment.
Findings:
- Cardiac hydatid disease is associated with significant morbidity and mortality.
- Complications include cyst rupture, anaphylaxis, and death.
Implications:
- Improved diagnostic strategies are needed for early detection.
- Minimizing surgical complications is essential for patient outcomes.
- Long-term monitoring and adherence to chemotherapy are critical.
Abstract:
Cardiac involvement in hydatid disease is rare, occurring in less than 2% of cases of hydatid infection. It can occur as part of a widespread systemic infection or as an isolated event. It may be asymptomatic for a long period before presenting with a myriad of non-specific symptoms. Imaging plays an important role in the diagnosis, surgical planning and follow up of cases. Current treatment involves attempted surgical resection (cystopericystectomy) with long-term follow-up chemotherapy (Albendazole). Both the disease and its surgical treatment carry a high complication rate, including rupture leading to anaphylaxis and death.